B. Riley analyst William Wood lowered the firm’s price target on Immunic (IMUX) to $5 from $6 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q1 report. Riley factored in the prospects of a likely near-term strategic financing to extend Immunic’s cash runway well beyond 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX:
- Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential
- Immunic’s Promising Clinical Data and Strategic Financial Position Justify Buy Rating
- Positive Phase 2 Trial Results for VidoCa in PMS Bolster Buy Rating for Immunic
- Biotech Alert: Searches spiking for these stocks today
- Promising Phase 2 Results for Vidofludimus Calcium in Progressive Multiple Sclerosis Highlight Potential for Neuroprotection and Disease Modification
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue